Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradation. Preclinical studies demonstrate that autophagy inhibition with hydroxychloroquine augments the anti...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Vogl, Dan T, Stadtmauer, Edward A, Tan, Kay-See, Heitjan, Daniel F, Davis, Lisa E, Pontiggia, Laura, Rangwala, Reshma, Piao, Shengfu, Chang, Yunyoung C, Scott, Emma C, Paul, Thomas M, Nichols, Charles W, Porter, David L, Kaplan, Janeen, Mallon, Gayle, Bradner, James E, Amaravadi, Ravi K
Médium: Artigo
Jazyk:Inglês
Vydáno: Landes Bioscience 2014
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4203515/
https://ncbi.nlm.nih.gov/pubmed/24991834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/auto.29264
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky